The RAS-Q® Solution

The RAS-Q® system will offer a new therapeutic approach for patients suffering from pulmonary hypertension. The device is based on conventional lung support technology, but also includes the lung’s flexible movement via a patented device-integrated compliance. This results in an extremely low flow resistance, allowing for lung support without the need for a blood pump. Therefore, mobilization of lung support patients will be possible for the first time while optimally treating pulmonary hypertension and reducing the afterload of the right heart.

Compliance

Lung and right heart stress relief improved by 90%

Low Resistance

Gold standard O2 and CO2 exchange at 80% lower pressure loss

Self-regulation

Recovery of physiological functions

Background

Background

Chronic obstructive pulmonary disease (COPD) is the 4th common cause of death whereby most of the cases are related to pulmonary hypertension (PH) and consecutive right heat failure.
In Germany, 236,644 hospitalizations due to PH were reported in 2014, with similar numbers in the other European countries. In the US, 728,983 hospitalizations and 21,292 deaths were reported in 2010, with an annual growth rate of ~10%. There is currently no cure available. Medication attenuates and prolongs the disease but is very costly at ~10.000 €/months.
No system is available to support these patients, because state-of-the-art technology is non-physiological, has high pressure loss and a high risk for thrombosis.

Partners and Sponsors

enmodes GmbH
enmodes GmbH
University Hospital Aachen
University Hospital Aachen
Clinic for Thoracic and Cardiovascular Surgery
Katholieke Universiteit Leuven
Katholieke Universiteit Leuven
Cardiac Surgery
University Witten/Herdecke
University Witten/Herdecke
Pulmonary clinic Köln/Merheim
Medical University of Vienna
Medical University of Vienna
Division of Cardiac Surgery
This activity has received funding from the European Institute of Innovation and Technology (EIT)
EIT receives support from the European Union's Horizon 2020 research and innovation programme
Zentrales Innovatosprogramm Mittelstand (ZIM)
Zentrales Innovatosprogramm Mittelstand (ZIM)

RAS-Q® will be the world’s first long-term respiratory assist device providing robust, fully portable, cost-effective and protective treatment of pulmonary hypertension patients.

News